Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) will report operational and financial results for its fiscal 2026 third quarter after market close on Wednesday, May 13, 2026. A conference call and webcast to review results is scheduled the same day at 4:30 p.m. ET.
Dial-in access, a live webcast link, and a teleconference replay through May 27, 2026, are available for investors and analysts.
Positive
- None.
Negative
- None.
News Market Reaction – AYTU
In the May 7 session, AYTU declined 3.52%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Earnings date notice | Neutral | +0.8% | Announced timing and access details for fiscal 2026 Q2 results call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior fiscal 2026 earnings date notice for Q2 saw a small positive move on the announcement.
Recent news for AYTU has centered on fiscal 2026 reporting and the EXXUA launch. The prior earnings date notice on Jan 27, 2026 preceded Q2 results and coincided with a modest 0.77% gain, while the actual Q2 report on Feb 3, 2026 saw a sharper decline. Against that backdrop, this Q3 earnings date announcement fits the ongoing cadence of scheduling result releases and associated calls for fiscal 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Wednesday, May 13, 2026, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 273453.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53861, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until May 27, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53861.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire